CDTX News and Press, Cidara Therapeutics Inc. From 08/16/23

Dr. Davarpanah will lead Cidara’s oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX)...

2023-08-10 17:50:45 ET Summary Cidara Therapeutics is a biotech company with an approved antifungal drug, Rezzayo, but its sales are not enough to offset expenses. The company's pipeline includes antifungal and antiviral agents, with CD388 being the most advanced drug in developme...

2023-08-03 17:37:53 ET Cidara Therapeutics press release ( NASDAQ: CDTX ): Q2 GAAP EPS of -$0.14 misses by $0.01 . Revenue of $7.61M (+22.3% Y/Y) misses by $3.94M . Shares -2.11% AH. For further details see: Cidara Therapeutics GAAP EPS of -$0.14 ...

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June ...

2023-08-01 09:36:30 ET A San Diego-based %Biotech company is turning heads Tuesday morning after the company announced that its partner, Melinta Therapeutics, has launched %Rezzayo , a treatment for candidemia and invasive candidiasis, in the US. According to the release, Rezzayo wa...

2023-07-31 18:46:32 ET Cidara Therapeutics ( NASDAQ: CDTX ) said that commercial partner Melinta Therapeutics has launched its recently approved antifungal drug Rezzayo in the US. Under their commercialization agreement , Cidara received $30M upfront and $20M for Rezzayo's F...

Cidara’s U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology...

2023-07-20 18:27:30 ET Cidara Therapeutics ( NASDAQ: CDTX ) said that its collaboration agreement with Johnson & Johnson's ( NYSE: JNJ ) Janssen Pharmaceuticals for its influenza drug candidate CD388 remains intact despite Janssen's decision to cease internal development...

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today provided an update on the status of its ongoing CD388 progra...

2023-06-26 13:22:15 ET Cidara Therapeutics ( NASDAQ: CDTX ) said Monday it has joined the broad market Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution. Press Release . For further details see: Cida...